Modality
Fusion Protein
MOA
TYK2i
Target
MALT1
Pathway
Ferroptosis
Parkinson'sMG
Development Pipeline
Preclinical
~Mar 2018
→ ~Jun 2019
Phase 1
~Sep 2019
→ ~Dec 2020
Phase 2
~Mar 2021
→ ~Jun 2022
Phase 3
Sep 2022
→ Jan 2030
Phase 3Current
NCT04823170
2,729 pts·Parkinson's
2022-09→2030-01·Completed
2,729 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-01-103mo agoEMA Filing· Parkinson's
2030-01-013.8y awayPh3 Readout· Parkinson's
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030
P3
Complet…
Catalysts
EMA Filing
2026-01-10 · 3mo ago
Parkinson's
Ph3 Readout
2030-01-01 · 3.8y away
Parkinson's
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04823170 | Phase 3 | Parkinson's | Completed | 2729 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET |